top of page
Scientific Publications
“KRFI for American Ibogaine initiative aims to unite with clinicians, researchers, advocates, scientists, policymakers, Indigenous leaders, and the plant medicine community to promote evidence-based medically approved prescriptive therapeutics. We seek to build mental health securities through education, policy engagement, in a global private public sector partnership where Indigenous Traditional Medicines can be integrated into the equitable health societies.”
1. Kohek, M., Ohren, M., Hornby, P., Alcázar‐Córcoles, M. Á., & Bouso, J. C. (2020). The ibogaine experience: A qualitative study on the acute subjective effects of ibogaine. Anthropology of Consciousness, 31(1), 91-119.
2. Ona, G., Rocha, J. M., Bouso, J. C., Hallak, J. E., Borras, T., Colomina, M. T., & Dos Santos, R. G. (2021). The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020). Psychopharmacology, 1-11.
3. International Center for Ethnobotanical Education, Research, and Service. (2020). Deciding to Take Iboga or Ibogaine. Accessed on October 26, 2022.
4. International Center for Ethnobotanical Education, Research, and Service. (2020). Iboga and Ibogaine Community Engagement Initiative Phase 1 Report. Accessed on October 26, 2022.
ABC
ABC
VLS-01: Society of Biological Psychiatry (SOBP) 2025 Poster(https://atai.com/wp-content/uploads/2025/04/VLS-01-_SOBP-Poster_2025-.png)
Szabo et al., The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells (2016)(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021697/)
Argento et al., Exploring ayahuasca‐assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada (2019)(https://onlinelibrary.wiley.com/doi/abs/10.1111/dar.12985)
Palhano-Fontes et al., Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression (2019)(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378413/)
Timmermann et al., Neural correlates of the DMT experience assessed with multivariate EEG (2019)(https://www.nature.com/articles/s41598-019-51974-4)
Pallavicini et al., Neural and subjective effects of inhaled DMT in natural settings (2020)(https://www.biorxiv.org/content/10.1101/2020.08.19.258145v1)
Pasquini et al., Subacute effects of the psychedelic ayahuasca on the salience and default mode networks (2020)(https://pubmed.ncbi.nlm.nih.gov/32255395/)
MAPS, MAPS – MDMA Investigator’s Brochure (10th Edition) (2018)(https://s3-us-west-1.amazonaws.com/mapscontent/research-archive/mdma/MAPS_2018_MDMA_Investigators_Brochure_Edition10_10JUL2018.pdf)
Rudnick & Wall, The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release (1992)(https://pmc.ncbi.nlm.nih.gov/articles/PMC48544/)
Carhart-Harris et al., The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity (2015)(https://pubmed.ncbi.nlm.nih.gov/24495461/)
Mitchell et al., MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021)(https://www.nature.com/articles/s41591-021-01336-3)
Mitchell et al., MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (2023)(https://www.nature.com/articles/s41591-023-02565-4)
ABC
Robertson, et al., Identification of Lead 5-HT2A Receptor Agonists for use in Treatment Resistant Depression with Non-hallucinogenic Potential and Low Valvulopathy Liability(https://atai.com/wp-content/uploads/2025/05/Discovery_BNA2025.pdf)
Bowen, et al., Discovery of novel 5-HT2A receptor agonists with non-hallucinogenic potential and translational antidepressant drug-like profiles(https://atai.com/wp-content/uploads/2025/02/2024_SfN_EGX_Poster-Final-printed-version-1.pdf)
Bowen, et al., Novel 5-HT2A receptor agonists exhibit translational antidepressant and psychedelic drug-like profiles in a model of treatment-resistant depression (2023)(https://atai.com/wp-content/uploads/2025/02/2023_SfN_ATAI_EGX-Neuroscience-Poster_For-External-Use-1.pdf)
Bowen, et al., Discovery of novel 5-HT2A receptor agonists with psychedelic drug-like in vitro and in vivo pharmacological activity and therapeutic potential for treatment-resistant depression (2023)(https://atai.com/wp-content/uploads/2025/02/2023_ACNP_ATAI_EGX-Scientific-Poster_For-External-Use-1.pdf)
Bowen, et al., Discovery of novel 5-HT2A receptor modulators for the treatment of mood disorders(https://atai.com/wp-content/uploads/2025/02/2022_SfN_ATAI_EntheogeniX-Scientific-Poster_180-x-120cm_20221027_V7.11-1.pdf)
bottom of page